Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
67
CPRX Quote, Financials, Valuation and Earnings
Last price:
$23.08
Seasonality move
:
1.44%
Day range:
$22.66 - $23.24
52-week range:
$19.05 - $26.58
Dividend yield:
0%
P/E ratio:
13.48x
P/S ratio:
5.07x
P/B ratio:
3.09x
Volume:
1M
Avg. volume:
1.3M
1-year change:
6.4%
Market cap:
$2.8B
Revenue:
$491.7M
EPS (TTM):
$1.71
Analysts' Opinion
-
Consensus RatingCatalyst Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $34.86, Catalyst Pharmaceuticals, Inc. has an estimated upside of 50.9% from its current price of $23.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $32.00 representing 100% downside risk from its current price of $23.10.
Fair Value
-
According to the consensus of 6 analysts, Catalyst Pharmaceuticals, Inc. has 50.9% upside to fair value with a price target of $34.86 per share.
CPRX vs. S&P 500
-
Over the past 5 trading days, Catalyst Pharmaceuticals, Inc. has underperformed the S&P 500 by -2.09% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Catalyst Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Catalyst Pharmaceuticals, Inc. has grown year-over-year revenues for 20 quarters straight. In the most recent quarter Catalyst Pharmaceuticals, Inc. reported revenues of $148.4M.
Earnings Growth
-
Catalyst Pharmaceuticals, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Catalyst Pharmaceuticals, Inc. reported earnings per share of $0.42.
Enterprise value:
2.2B
EV / Invested capital:
2.33x
Price / LTM sales:
5.07x
EV / EBIT:
8.32x
EV / Revenue:
3.72x
PEG ratio (5yr expected):
0.29x
EV / Free cash flow:
9.18x
Price / Operating cash flow:
12.51x
Enterprise value / EBITDA:
7.26x
Gross Profit (TTM):
$458M
Return On Assets:
23.86%
Net Income Margin (TTM):
37.63%
Return On Equity:
27.48%
Return On Invested Capital:
27.37%
Operating Margin:
44.66%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $348.4M | $460.5M | $578.2M | $128.7M | $148.4M | |
| Gross Profit | $277.5M | $360.4M | $458M | $100.1M | $116.4M | |
| Operating Income | $75.9M | $174M | $258.8M | $50.9M | $66.3M | |
| EBITDA | $100.5M | $211.6M | $296.6M | $60.4M | $75.7M | |
| Diluted EPS | $0.53 | $1.17 | $1.71 | $0.35 | $0.42 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $192.8M | $276.3M | $192M | $539M | $852.5M | |
| Total Assets | $223.2M | $333.1M | $413.2M | $772M | $1.1B | |
| Current Liabilities | $20.6M | $44.7M | $57.8M | $105.4M | $128.7M | |
| Total Liabilities | $24.6M | $63.1M | $64.7M | $111.1M | $131.4M | |
| Total Equity | $198.7M | $270M | $348.5M | $660.9M | $920.2M | |
| Total Debt | $4.3M | $3.6M | $3.3M | $2.9M | $2.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $128M | $224.6M | $234.7M | $72.9M | $32.4M | |
| Cash From Investing | -$255.2M | -$38.8M | -$114K | -$259K | -- | |
| Cash From Financing | -$7.9M | $135.6M | $13M | -$6M | $4.7M | |
| Free Cash Flow | -$34.4M | $188M | $234.5M | $72.6M | $32.4M | |
CPRX
Sector
Market Cap
$2.8B
$28.4M
Price % of 52-Week High
86.91%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-0.77%
-1.32%
1-Year Price Total Return
6.4%
-22.19%
Beta (5-Year)
0.685
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$23.20
200-day SMA
Buy
Level
$22.06
Bollinger Bands (100)
Buy
Level
19.94 - 22.06
Chaikin Money Flow
Sell
Level
-8.1M
20-day SMA
Buy
Level
$22.68
Relative Strength Index (RSI14)
Buy
Level
58.68
ADX Line
Buy
Level
34.75
Williams %R
Neutral
Level
-48.5207
50-day SMA
Buy
Level
$21.48
MACD (12, 26)
Buy
Level
0.50
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (14.4346)
Buy
CA Score
(Annual)
Level (2.7179)
Buy
Beneish M-Score
(Annual)
Level (-2.8639)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-6.7686)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
Stock Forecast FAQ
In the current month, CPRX has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CPRX average analyst price target in the past 3 months is $34.86.
-
Where Will Catalyst Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Catalyst Pharmaceuticals, Inc. share price will rise to $34.86 per share over the next 12 months.
-
What Do Analysts Say About Catalyst Pharmaceuticals, Inc.?
Analysts are divided on their view about Catalyst Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Catalyst Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $32.00.
-
What Is Catalyst Pharmaceuticals, Inc.'s Price Target?
The price target for Catalyst Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $34.86 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CPRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Catalyst Pharmaceuticals, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CPRX?
You can purchase shares of Catalyst Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Catalyst Pharmaceuticals, Inc. shares.
-
What Is The Catalyst Pharmaceuticals, Inc. Share Price Today?
Catalyst Pharmaceuticals, Inc. was last trading at $23.08 per share. This represents the most recent stock quote for Catalyst Pharmaceuticals, Inc.. Yesterday, Catalyst Pharmaceuticals, Inc. closed at $23.10 per share.
-
How To Buy Catalyst Pharmaceuticals, Inc. Stock Online?
In order to purchase Catalyst Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CPRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CPRX
Sector
P/E ratio
13.48x
23.66x
PEG ratio
0.29x
-0.01x
P/B ratio
3.09x
1.84x
Price / LTM sales
5.07x
1.60x
Growth Metrics
CPRX
Sector
Revenue growth
15.31%
4.85%
Earnings growth
18.69%
11.15%
Revenue (5-year growth)
36.89%
6.45%
Earnings forecast
$0.54
-$0.20
Profitability
CPRX
Sector
Profitability FY 2024
$385.5M
$3.6M
Return on invested capital
27.37%
-30.98%
Return on assets
23.86%
-27.62%
Return on equity
27.48%
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
4
Balance Sheet
CPRX
Sector
Total cash
$689.9M
$27.2M
Short term investments
--
$25.7M
Total assets
$854.5M
$79.9M
Long term debt
$2.5M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
